Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fennec Pharmaceuticals Inc PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 USA

www.fennecpharma.com Employees: 35 P: 919-636-4530

Sector:

Medical

Description:

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 224,087
Enterprise Value, $K 187,297
Shares Outstanding, K 34,475
Float, K 30,421
% Float 88.24%
Short Interest, K 913
Short Float 2.65%
Days to Cover 2.96
Short Volume Ratio 0.86
% of Insider Shareholders 11.76%
% of Institutional Shareholders 55.51%

Financials:

Annual Sales, $ 44,640 K
Annual Net Income, $ -9,740 K
Last Quarter Sales, $ 13,780 K
Last Quarter Net Income, $ -4,790 K
EBIT, $ -6,280 K
EBITDA, $ -6,110 K

Growth:

1-Year Return 23.53%
3-Year Return -18.18%
5-Year Return 83.67%
5-Year Revenue Growth 26,158.82%
5-Year Earnings Growth 63.16%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 03/24/26
Next Earnings Date 05/12/26 [--]
Earnings Per Share ttm -0.28
EPS Growth vs. Prev Qtr -450.00%
EPS Growth vs. Prev Year -83.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 11/29/21

FENC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 20.66
Price/Earnings to Growth N/A
Return-on-Equity % -183.18%
Return-on-Assets % -15.31%
Profit Margin % -21.82%
Debt/Equity 0.00
Price/Sales 4.83
Price/Cash Flow N/A
Price/Book 6.02
Book Value/Share 1.04
Interest Coverage -3.63
60-Month Beta 0.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.